

Myrthe P P Van Herk-Sukel

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7419876/myrthe-p-p-van-herk-sukel-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

16

papers

513

citations

10

h-index

16

g-index

16

ext. papers

569

ext. citations

3.4

avg, IF

2.91

L-index

#	Paper	IF	Citations
16	Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2423-9	2.2	126
15	New opportunities for drug outcomes research in cancer patients: the linkage of the Eindhoven Cancer Registry and the PHARMO Record Linkage System. <i>European Journal of Cancer</i> , 2010 , 46, 395-404	7.5	93
14	Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis. <i>Breast Cancer Research and Treatment</i> , 2010 , 122, 843-51	4.4	86
13	Three-year dispensing patterns with long-acting inhaled drugs in COPD: a database analysis. <i>Respiratory Medicine</i> , 2011 , 105, 259-65	4.6	38
12	Prescribing of rosiglitazone and pioglitazone following safety signals: analysis of trends in dispensing patterns in the Netherlands from 1998 to 2008. <i>Drug Safety</i> , 2012 , 35, 471-80	5.1	32
11	Aspirin use after diagnosis improves survival in older adults with colon cancer: a retrospective cohort study. <i>Journal of the American Geriatrics Society</i> , 2012 , 60, 2232-6	5.6	30
10	Prevalence and incidence of acute and chronic comorbidity in patients with squamous cell carcinoma of the head and neck. <i>Head and Neck</i> , 2012 , 34, 238-44	4.2	25
9	Record linkage for pharmacoepidemiological studies in cancer patients. <i>Pharmacoepidemiology and Drug Safety</i> , 2012 , 21, 94-103	2.6	23
8	Use and costs of oral anticancer agents in the Netherlands in the period 2000-2008. <i>Pharmacoepidemiology and Drug Safety</i> , 2012 , 21, 1036-44	2.6	16
7	Gastroprotection among new chronic users of non-steroidal anti-inflammatory drugs: a study of utilization and adherence in The Netherlands. <i>Current Medical Research and Opinion</i> , 2009 , 25, 195-204	2.5	14
6	COX-2 inhibitors: complex association with lower risk of hospitalization for gastrointestinal events compared to traditional NSAIDs plus proton pump inhibitors. <i>Pharmacoepidemiology and Drug Safety</i> , 2009 , 18, 880-90	2.6	7
5	Occurrence of Comorbidities before and after Soft Tissue Sarcoma Diagnosis. <i>Sarcoma</i> , 2012 , 2012, 402109	1.09	7
4	Prescription behavior for gastroprotective drugs in new users as a result of communications regarding clopidogrel - proton pump inhibitor interaction. <i>Pharmacology Research and Perspectives</i> , 2016 , 4, e00242	3.1	7
3	Costs of hospital events in patients with metastatic colorectal cancer. <i>Journal of Medical Economics</i> , 2011 , 14, 656-61	2.4	6
2	Use of Topical Tacrolimus and Topical Pimecrolimus in Four European Countries: A Multicentre Database Cohort Study. <i>Drugs - Real World Outcomes</i> , 2018 , 5, 109-116	2.2	2
1	Decrease in Switches to Unsafed Proton Pump Inhibitors After Communications About Interactions with Clopidogrel. <i>Clinical Drug Investigation</i> , 2017 , 37, 787-794	3.2	1